GRDX - Entero Therapeutics, Inc.
2.42
-0.370 -15.289%
Share volume: 203,774
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$2.79
-0.37
-0.13%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 10-21-2024 | 11-13-2024 | 05-15-2025 | 08-14-2025 | 11-19-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 9.226 M | 3.426 M | 1.893 M | 821.386 K | 638.864 K | 934.787 K | |
| Selling general and admin | 8.660 M | 3.207 M | 1.686 M | 805.559 K | 628.233 K | 928.114 K | |
| Research and development | 565.962 K | 219.591 K | 206.999 K | 15.827 K | 10.631 K | 6.673 K | |
| Total expenses | 9.226 M | 3.426 M | 1.893 M | 821.386 K | 638.864 K | 934.787 K | |
| -62.86% | -44.76% | -56.60% | -22.22% | 46.32% | |||
| Operating income | -9.226 M | -3.426 M | -1.893 M | -821.386 K | -638.864 K | -934.787 K | |
| Ebit | -9.226 M | -3.430 M | -1.895 M | -930.203 K | -638.864 K | -934.787 K | |
| Pretax income | -9.292 M | -3.430 M | -1.895 M | -948.105 K | -674.931 K | -970.856 K | |
| -63.09% | -44.75% | -49.97% | -28.81% | 43.85% | |||
| Income tax | -14.860 M | 4.255 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 5.568 M | -8.808 M | -2.581 M | -1.260 M | -998.271 K | -1.153 M | |
| -258.20% | 70.70% | 51.20% | 20.75% | -15.48% |